Nocturnal plasma delta sleep-inducing peptide-like immunoreactivity (DSIP-LI) was determined serially in seven healthy male subjects. Time courses during nocturnal sleep (2300-0800 h), nocturnal sleep deprivation (2300-0500 h), and morning recovery sleep (0500-0800 h) after sleep deprivation were compared. A significant decrease in plasma DSIP-LI was found at the transition from wakefulness to sleep in both evening sleep (2300 h) and morning recovery sleep (0500 h). Time courses were accompanied by physiological changes in sleep electroencephalographic slow-wave activity, and in plasma concentrations of cortisol and human growth hormone. No sleep stage specificity was found. It is concluded that DSIP is influenced by the initiation of sleep.
"A close correlation between the diurnal rhythm of DSIP-LI and that of body temperature was detected. It was concluded that endogenous elevation of DSIP may be associated with suppression of both SWS and paradoxical sleep (PS), and that the circadian rhythm of DSIP is coupled directly or indirectly to that of body temperature (Friedman et al. 1994b; Schulz et al. 1994; Seifritz et al. 1995; Steiger and Holsboer 1997); (iv) cardiotropic and vasomotor activity (DSIP can normalize blood pressure and myocardial contraction; Schoenenberger 1984; Yehuda et al. 1988; Inoué 1989; Prudchenko et al. 1994; Strekalova 1998); (v) pain, where DSIP can produce an analgesic effect by augmenting met-encephalin binding with opiate receptors (Schoenenberger 1984; Yehuda et al. 1988; Inoué et al. 1990; Prudchenko et al. 1994; Lysenko et al. 1995; Strekalova 1998; Pollard and Pomfrett 2001); (vi) regulation of diurnal and circadian rhythmicity (Friedman et al. 1994b; Schulz et al. 1994; Seifritz et al. 1995 ; Vgontzas et al. 1995) ; ( vii) anti - opioid and anti - alcohol activity ( DSIP can suppress the development of alcohol and opiate dependency this being the basis for DSIP clinical application ; Yukhana - nov et al. 1991 , 1992 ; Soyka and Rothenhaeusler 1997 ; Backmund et al . 1998 ; Hruz et al . "
[Show abstract][Hide abstract] ABSTRACT: Delta sleep-inducing peptide (DSIP) was isolated from rabbit cerebral venous blood by Schoenenberger-Monnier group from Basel in 1977 and initially regarded as a candidate sleep-promoting factor. However, the link between DSIP and sleep has never been further characterized, in part because of the lack of isolation of the DSIP gene, protein and possible related receptor. Thus the hypothesis regarding DSIP as a sleep factor is extremely poorly documented and still weak. Although DSIP itself presented a focus of study for a number of researchers, its natural occurrence and biological activity still remains obscure. DSIP structure is different from any other known representative of the various peptide families. In this mini-review we hypothesize the existence of a DSIP-like peptide(s) that is responsible (at least partly) for DSIP-like immunoreactivity and DSIP biological activity. This assumption is based on: (i) a highly specific distribution of DSIP-like immunoreactivity in the neurosecretory hypothalamic nuclei of various vertebrate species that are not particularly relevant for sleep regulation, as revealed by the histochemical studies of the Geneva group (Charnay et al.); (ii) a large spectrum of DSIP biological activity revealed by biochemical and physiological studies in vitro; (iii) significant slow-wave sleep (SWS) promoting activity of certain artificial DSIP structural analogues (but not DSIP itself!) in rabbits and rats revealed by our early studies; and (iv) significant SWS-promoting activity of a naturally occurring dermorphin-decapeptide that is structurally similar to DSIP (in five of the nine positions) and the sleep-suppressing effect of its optical isomer, as revealed in rabbits. Potential future studies are outlined, including natural synthesis and release of this DSIP-like peptide and its role in neuroendocrine regulation.
Journal of Neurochemistry 05/2006; 97(2):303-9. DOI:10.1111/j.1471-4159.2006.03693.x · 4.28 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Effects of peptides on the central nervous system are presented in two ways so as to provide a cross-listing. In the first table, the peptides are listed alphabetically. In the second table, the central nervous system effects are arranged alphabetically. No longer can there be any doubt that peptides affect the central nervous system, sometimes in several ways.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.